This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia

This study has suspended participant recruitment.
Information provided by:
Hamamatsu University Identifier:
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
Dopamine has been closely associated with prefrontal function. The hypothesis that a lower dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed in the patients of schizophrenia is of a heuristic value in guiding research in this area. This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve negative symptoms and cognitive impairments prevailing in most patients with schizophrenia. This double-blind placebo controlled study will investigate the remedial effect of pergolide on negative symptoms and cognitive impairments in schizophrenia.

Condition Intervention Phase
Schizophrenia Negative Symptoms Cognitive Impairments Drug: Pergolide (drug) Phase 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Effective Adjunctive Use of Pergolide With Risperidone for Cognitive Impairment and Negative Symptoms in Schizophrenia

Resource links provided by NLM:

Further study details as provided by Hamamatsu University:

Estimated Enrollment: 20
Study Start Date: March 2003

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  • Were age 18–50 years, met the DSM-IV criteria for schizophrenia
  • Were treated with a stable dose of risperidone, raging 2 to 6mg, for more than 8 weeks
  • Had a score ≥15 on negative subscale items in Positive and Negative Syndrome Scale (PANSS)
  • Had a minimum period of symptom stability, defined as no more than 20% change on consecutive ratings on PANSS for at lease 4 weeks

Exclusion Criteria:

  • Had a history of medical condition or drug treatment that may have affected cognitive performance
  • Had a history of other psychiatric disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00197483

Hamamatsu University Hospital
Hamamatsu, Shizuoka, Japan, 431-3192
Sponsors and Collaborators
Hamamatsu University
Study Chair: Norio Mori, Ph.D Hamamatsu University, School of Medicine, Department of Psychiatry and Neurology
  More Information

Publications: Identifier: NCT00197483     History of Changes
Other Study ID Numbers: 01T-080
Study First Received: September 13, 2005
Last Updated: September 13, 2005

Keywords provided by Hamamatsu University:
Dopamine D1
Cognitive disturbance
Negative symptoms

Additional relevant MeSH terms:
Cognition Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Neurocognitive Disorders
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on September 21, 2017